"Seeing is believing": Perspectives of applying imaging technology in discovery toxicology

Combinatorial Chemistry and High Throughput Screening

Volumn 12, Issue 9, 2009, Pages 827-837

  Xu, Jinghai James ^a,b   Dunn, Margaret Condon ^a   Smith, Arthur Russell ^a  

^a PFIZER INC   (United States)

^b NONE   (United States)

Author keywords

Ames; Cardiac safety screens; Cardiotoxicity test; Genetic toxicology; Hepatotoxicity; Idiosyncratic drug induced liver injury; Lead optimization; Micronucleus; Phospholipidosis; Translational medicine

Indexed keywords

ACETYLSALICYLIC ACID; AMIKACIN; AMITRIPTYLINE; CHLORZOXAZONE; DANTROLENE; DICLOFENAC; FAMOTIDINE; FLUOXETINE; FUROSEMIDE; ISONIAZID; KETOTIFEN; LABETALOL; MELATONIN; NADOLOL; NEFAZODONE; NIMESULIDE; PARACETAMOL; PAROMOMYCIN; PENICILLIN G; PERHEXILINE; PIOGLITAZONE; PRIMIDONE; PROBENECID; ROSIGLITAZONE; SULINDAC; SUMATRIPTAN; TETRACYCLINE; TROGLITAZONE; UNINDEXED DRUG; ZILEUTON;

CARDIOTOXICITY; CHROMOSOME DAMAGE; COMPARATIVE TOXICOLOGY; CYTOTOXICITY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; GENETIC TOXICOLOGY; HIGH THROUGHPUT SCREENING; HUMAN; IMAGE ANALYSIS; IMAGING; LIPIDOSIS; LIVER TOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TOXICOLOGY; TRANSGENICS;

ANIMALS; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; TOXICOLOGY;

EID: 70349466663     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620709789383268     Document Type: Review

References (57)

1. Hopkins, A.L.; Groom, C.R. The druggable genome. Nat. Rev. Drug Discov., 2002, 1(9), 727-730.
2. Pereira, D.A.; Williams, J.A. Origin and evolution of high throughput screening. Br. J. Pharmacol., 2007, 152(1), 53-61.
3. Giacomini, K.M.; Krauss, R.M.; Roden, D.M.; Eichelbaum, M.; Hayden, M.R.; Nakamura, Y. When good drugs go bad. Nature, 2007, 446(7139), 975-977.
4. DDTSS, The Drug Discovery Toxicology Specialty Section of the Society of Toxicology. 2004, http://www.toxicology.org/ISOT/SS/DDTSS [Accessed on January 9, 2007].
5. Kramer, J.A.; Sagartz, J.E.; Morris, D.L. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discov., 2007, 6(8), 636-649.
6. Mayne, J.T.; Ku, W.W.; Kennedy, S.P. Informed toxicity assessment in drug discovery: systems-based toxicology. Curr. Opin. Drug Discov. Devel., 2006, 9(1), 75-83. (Pubitemid 43102529)
7. Zambrowicz, B.P.; Sands, A.T. Knockouts model the 100 bestselling drugs - will they model the next 100? Nat. Rev. Drug Discov., 2003, 2(1), 38-51.
8. Dambach, D.M. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr. Top. Med. Chem., 2005, 5(10), 929-939. (Pubitemid 41582125)
9. Xu, J.J.; Diaz, D.; O'Brien, P.J. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem. Biol. Interact., 2004, 150(1), 115-128.
10. Xu, J.J.; Dunn, M.C.; Smith, A.R. Applications of Cell-Based Imaging Technologies in Toxicity Screening in Drug Discovery and Development. Am. Drug Discov., 2006, 1(1), 20-26.
11. Abraham, V.C.; Taylor, D.L.; Haskins, J.R. High content screening applied to large-scale cell biology. Trends Biotechnol., 2004, 22(1), 15-22.
12. Miller, J.E.; Vlasakova, K.; Glaab, W.E.; Skopek, T.R. A low volume, high-throughput forward mutation assay in Salmonella typhimurium based on fluorouracil resistance. Mutat. Res., 2005, 578(1-2), 210-224.
13. Flamand, N.; Meunier, J.; Meunier, P.; Agapakis-Causse, C. Mini mutagenicity test: a miniaturized version of the Ames test used in a prescreening assay for point mutagenesis assessment. Toxicol. In Vitro, 2001, 15(2), 105-114. (Pubitemid 32245689)
14. McCann, J.; Ames, B.N. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals: discussion. Proc. Natl. Acad. Sci. USA, 1976, 73(3), 950-954.
15. Cote, C.; Blaise, C.; Delisle, C.E.; Meighen, E.A.; Hansen, P.D. A miniaturized Ames mutagenicity assay employing bioluminescent strains of Salmonella typhimurium. Mutat. Res., 1995, 345(3-4), 137-146.
16. Pfuhler, S.; Albertini, S.; Fautz, R.; Herbold, B.; Madle, S.; Utesch, D.; Poth, A. Genetic toxicity assessment: employing the best science for human safety evaluation part IV: Recommendation of a working group of the Gesellschaft fuer Umwelt-Mutationsforschung (GUM) for a simple and straightforward approach to genotoxicity testing. Toxicol. Sci., 2007, 97(2), 237-240. (Pubitemid 47073841)
17. Kirsch-Volders, M.; Sofuni, T.; Aardema, M.; Albertini, S.; Eastmond, D.; Fenech, M.; Ishidate, M., Jr.; Kirchner, S.; Lorge, E.; Morita, T.; Norppa, H.; Surralles, J.; Vanhauwaert, A.; Wakata, A., Report from the in vitro micronucleus assay working group. Mutat. Res., 2003, 540(2), 153-163. (Pubitemid 37209943)
18. Xu, J.J.; Dunn, M.C.; Ryley, L.C. Automated in vitro cellular imaging assays for micronuclei and other target objects. 2003, http://v3.espacenet.com/ origdoc?DB=EPODOC&IDX=WO2004099773&F=0&QPN=WO2004099773.
19. Draviam, V.M.; Stegmeier, F.; Nalepa, G.; Sowa, M.E.; Chen, J.; Liang, A.; Hannon, G.J.; Sorger, P.K.; Harper, J.W.; Elledge, S.J. A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling. Nat. Cell Biol., 2007, 9(5), 556-564.
20. Kaplowitz, N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov., 2005, 4(6), 489-499.
21. Olson, H.; Betton, G.; Robinson, D.; Thomas, K.; Monro, A.; Kolaja, G.; Lilly, P.; Sanders, J.; Sipes, G.; Bracken, W.; Dorato, M.; Van Deun, K.; Smith, P.; Berger, B.; Heller, A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol., 2000, 32(1), 56-67. (Pubitemid 30764600)
22. Liu, Z.X.; Kaplowitz, N. Role of innate immunity in acetaminophen-induced hepatotoxicity. Expert Opin. Drug Metab. Toxicol., 2006, 2(4), 493-503. (Pubitemid 46118323)
23. Ong, M.M. Latchoumycandane, C.; Boelsterli, U. A., Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol. Sci., 2007, 97(1), 205-213.
24. Boelsterli, U.A.; Ho, H.K.; Zhou, S.; Leow, K.Y. Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr. Drug Metab., 2006, 7(7), 715-727.
25. Kokoszka, J.E.; Coskun, P.; Esposito, L.A.; Wallace, D.C. Increased mitochondrial oxidative stress in the Sod2 (+/-) mouse results in the age-related decline of mitochondrial function culminating in increased apoptosis. Proc. Natl. Acad. Sci. USA, 2001, 98(5), 2278-2283.
26. Lee, W.M., Drug-induced hepatotoxicity. N. Engl. J. Med., 2003, 349(5), 474-485.
27. Bi, Y.A.; Kazolias, D.; Duignan, D.B. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab. Dispos., 2006, 34(9), 1658-1665.
28. Shah, R.R. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics, 2006, 7(6), 889-908.
29. Scheen, A. J., Thiazolidinediones and liver toxicity. Diabetes Metab., 2001, 27(3), 305-313.
30. Choi, S. Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ., 2003, 169(11), 1187.
31. Thiim, M.; Friedman, L. S. Hepatotoxicity of antibiotics and antifungals. Clin. Liver Dis., 2003, 7(2), 381-399, vi-vii.
32. Aithal, G.P.; Day, C.P. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin. Liver Dis., 2007, 11(3), 563-575.
33. Temple, R., Hepatotoxicity through the years: impact on the FDA. at http://www.fda.gov/cder/ livertox/Presenta tions/im1389/tsld001.html [Accessed on January 9, 2007].
34. Sancilio, L., Phospholipidosis Working Group (FDA), 2004, at http://www.nyas.org/events/event Detail.asp?eventI D=5769&date=3/30/ 2006%204:30:00%20PM [Accessed on January 9, 2007]
35. Gum, R.J.; Hickman, D.; Fagerland, J.A.; Heindel, M.A.; Gagne, G.D.; Schmidt, J.M.; Michaelides, M.R.; Davidsen, S.K.; Ulrich, R.G. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes(1). Biochem. Pharmacol., 2001, 62(12), 1661-1673.
36. Dumotier, B.M.; Georgieva, A.V. Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: the inseparable twins. Cell Biol. Toxicol., 2007, 23(4), 293-302.
37. Milan, D.J.; Jones, I.L.; Ellinor, P.T.; MacRae, C.A. In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation. Am. J. Physiol. Heart Circ. Physiol., 2006, 291(1), H269-273.
38. Sanguinetti, M.C.; Curran, M.E.; Spector, P.S.; Keating, M.T. Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. Proc. Natl. Acad. Sci. USA, 1996, 93(5), 2208-2212.
39. Guth, B.D. Preclinical cardiovascular risk assessment in modern drug development. Toxicol. Sci. 2007, 97(1), 4-20.
40. Rubinstein, A. L., Zebrafish assays for drug toxicity screening. Expert Opin. Drug Metab. Toxicol., 2006, 2(2), 231-240.
41. Carney, S. A.; Chen, J.; Burns, C.G.; Xiong, K.M.; Peterson, R.E.; Heideman, W. Aryl hydrocarbon receptor activation produces heart-specific transcriptional and toxic responses in developing zebrafish. Mol. Pharmacol. 2006, 70(2), 549-561. (Pubitemid 44092316)
42. Reimers, M. J.; La Du, J. K.; Periera, C. B.; Giovanini, J.; Tanguay, R. L., Ethanol-dependent toxicity in zebrafish is partially attenuated by antioxidants. Neurotoxicol. Teratol., 2006, 28(4), 497-508.
43. Hamm, E.E.; Voth, D.E.; Ballard, J.D. Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc. Natl. Acad. Sci. USA, 2006, 103(38), 14176-14181.
44. Burns, C.G.; Milan, D.J.; Grande, E.J.; Rottbauer, W.; MacRae, C.A.; Fishman, M.C. High-throughput assay for small molecules that modulate zebrafish embryonic heart rate. Nat. Chem. Biol., 2005, 1(5), 263-264.
45. Gervais-Pingot, V.; Legrand, J J.; Nasr, G.; Schoevaert, D. In vitro quantification by image analysis of inotropic and chronotropic effects of drugs on cultures of cardiac myocytes. Cell Biol. Toxicol., 1994, 10(5-6), 297-300. (Pubitemid 24377301)
46. Hove-Madsen, L.; Llach, A.; Molina, C.E.; Prat-Vidal, C.; Farre, J.; Roura, S.; Cinca, J. The proarrhythmic antihistaminic drug terfenadine increases spontaneous calcium release in human atrial myocytes. Eur. J. Pharmacol., 2006, 553(1-3), 215-221. (Pubitemid 44779593)
47. Poindexter, B.J.; Feng, W.; Dasgupta, A.; Bick, R.J. Oleandrin produces changes in intracellular calcium levels in isolated cardiomyocytes: a real-time fluorescence imaging study comparing adult to neonatal cardiomyocytes. J. Toxicol. Environ. Health A, 2007, 70(6), 568-574.
48. Khan, M.; Varadharaj, S.; Shobha, J.C.; Naidu, M. U.; Parinandi, N. L.; Kutala, V. K.; Kuppusamy, P., C-phycocyanin ameliorates doxorubicin-induced oxidative stress and apoptosis in adult rat cardiomyocytes. J. Cardiovasc. Pharmacol., 2006, 47(1), 9-20. (Pubitemid 44378219)
49. Wang, S.Q.; Wei, C.; Zhao, G.; Brochet, D. X.; Shen, J.; Song, L. S.; Wang, W.; Yang, D.; Cheng, H., Imaging microdomain Ca2+ in muscle cells. Circ. Res., 2004, 94(8), 1011-1022. (Pubitemid 38579695)
50. Fast, V.G. Simultaneous optical imaging of membrane potential and intracellular calcium. J. Electrocardiol., 2005, 38(4 Suppl), 107-112.
51. Kouri, K.; Duchen, M.R.; Lemmens-Gruber, R. Effects of beauvericin on the metabolic state and ionic homeostasis of ventricular myocytes of the guinea pig. Chem. Res. Toxicol., 2005, 18(11), 1661-1668. (Pubitemid 43257747)
52. Demuro, A.; Parker, I. "Optical patch-clamping": single-channel recording by imaging Ca2+ flux through individual muscle acetylcholine receptor channels. J. Gen. Physiol., 2005, 126(3), 179-192. (Pubitemid 41252780)
53. Pentassuglia, L.; Timolati, F.; Seifriz, F.; Abudukadier, K.; Suter, T. M.; Zuppinger, C. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp. Cell Res., 2007, 313(8), 1588-1601. (Pubitemid 46589436)
54. Wang, L.; Wible, B.A.; Wan, X.; Ficker, E. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J. Pharmacol. Exp. Ther., 2007, 320(2), 525-534. (Pubitemid 46147930)
55. Hancox, J.C.; Mitcheson, J.S. Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology. Br. J. Pharmacol., 2006, 149(5), 457-459. (Pubitemid 44658505)
56. Ficker, E.; Dennis, A.; Kuryshev, Y.; Wible, B.A.; Brown, A.M. HERG channel trafficking. Novartis Found. Symp., 2005, 266, 57-69; discussion 70-4, 95-99.
57. Wible, B.A.; Hawryluk, P.; Ficker, E.; Kuryshev, Y.A.; Kirsch, G.; Brown, A.M. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. Toxicol. Methods, 2005, 52(1), 136-145.